Enabling Extraordinary Lives for Sickle Cell Disease Patients

learn more »

Transforming Treatment of Severe Blood Disorders

learn more »

A Commitment to Serving Patients and Their Families

learn more »

Innovative Science

Through its scientific foundation, Global Blood Therapeutics (GBT) is committed to transforming the treatment of severe blood disorders. 

Unlike current drugs that treat symptoms during acute episodes, GBT is developing novel small molecule therapeutics that disrupt the fundamental pathophysiology of the disorders.

more »

Spotlight on GBT440

Discovered internally at Global Blood Therapeutics, GBT440 is an oral, once daily, direct-acting hemoglobin modifier for the chronic, prophylactic treatment of patients with sickle cell disease (SCD).

With the promise of restoring normal hemoglobin function, GBT440 may be capable of arresting the progression of SCD.

more »